Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan

Show simple item record

dc.contributor.author Saito, Akiko M. en_US
dc.contributor.author Kami, Masahiro en_US
dc.contributor.author Mori, Shin-Ichiro en_US
dc.contributor.author Kanda, Yoshinobu en_US
dc.contributor.author Suzuki, Ritsuro en_US
dc.contributor.author Mineishi, Shin en_US
dc.contributor.author Takami, Akiyoshi en_US
dc.contributor.author Taniguchi, Shuichi en_US
dc.contributor.author Takemoto, Yoshinobu en_US
dc.contributor.author Hara, Masamichi en_US
dc.contributor.author Yamaguchi, Masaki en_US
dc.contributor.author Hino, Masayuki en_US
dc.contributor.author Yoshida, Takashi en_US
dc.contributor.author Kim, Sung-Won en_US
dc.contributor.author Hori, Akiko en_US
dc.contributor.author Ohashi, Yasuo en_US
dc.contributor.author Takaue, Yoichi en_US
dc.date.accessioned 2007-09-20T19:03:25Z
dc.date.available 2008-11-05T15:05:43Z en_US
dc.date.issued 2007-10 en_US
dc.identifier.citation Saito, Akiko M.; Kami, Masahiro; Mori, Shin-Ichiro; Kanda, Yoshinobu; Suzuki, Ritsuro; Mineishi, Shin; Takami, Akiyoshi; Taniguchi, Shuichi; Takemoto, Yoshinobu; Hara, Masamichi; Yamaguchi, Masaki; Hino, Masayuki; Yoshida, Takashi; Kim, Sung-Won; Hori, Akiko; Ohashi, Yasuo; Takaue, Yoichi (2007)."Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan." American Journal of Hematology 82(10): 873-880. <http://hdl.handle.net/2027.42/56131> en_US
dc.identifier.issn 0361-8609 en_US
dc.identifier.issn 1096-8652 en_US
dc.identifier.uri http://hdl.handle.net/2027.42/56131
dc.identifier.uri http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17570513&dopt=citation
dc.description.abstract This prospective trial assessed the safety and efficacy of allogeneic hematopoietic stem cell transplantation from a HLA-matched donor with a reduced-intensity regimen (RIST) consisting of iv fludarabine 30 mg/m 2 for 6 days and oral busulfan 4 mg/kg/day for 2 days in patients older than 50 years with hematological malignancies. Cyclosporine alone or cyclosporine with short-term methotrexate was randomized for graft-versus-host disease prophylaxis. After 30 patients had been enrolled, an interim analysis was performed, and this report focuses on a precise evaluation of the toxicity profile and chimerism kinetics. Sustained engraftment in all patients, no severe regimen-related toxicity (RRT) within 20 days, and no transplant-related mortality through Day 100 were observed. T-cell (CD3+) full-donor (over 90%) chimerism was observed in 22 of the 30 patients, while the remaining eight had mixed-donor chimerism over 77% on Day 90. Thereafter, five subsequently converted to full-donor chimerism without donor lymphocyte infusion by day 120 ( n = 4) or Day 180 ( n = 1). Two showed persistent mixed chimerism without relapse through Day 180. Grade III–IV acute graft-versus-host disease and extensive chronic graft-versus-host disease occurred in 10% and 73%, respectively. With a median follow-up of 1.5 years, overall survival and disease-free survival at 1 year was 83% and 62%, respectively. Seven patients hematologically relapsed overall, and five of them had myelodysplastic syndrome with poor prognostic factors. In older patients, RIST with fludarabine and busulfan was associated with acceptable toxicities and a satisfactory antileukemia effect, regardless of the early chimerism status. Am. J. Hematol. 82:873–880, 2007. © 2007 Wiley-Liss, Inc. en_US
dc.format.extent 169974 bytes
dc.format.extent 3118 bytes
dc.format.mimetype application/pdf
dc.format.mimetype text/plain
dc.publisher Wiley Subscription Services, Inc., A Wiley Company en_US
dc.subject.other Life and Medical Sciences en_US
dc.subject.other Cancer Research, Oncology and Pathology en_US
dc.title Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan en_US
dc.type Article en_US
dc.rights.robots IndexNoFollow en_US
dc.subject.hlbsecondlevel Molecular, Cellular and Developmental Biology en_US
dc.subject.hlbsecondlevel Oncology and Hematology en_US
dc.subject.hlbtoplevel Health Sciences en_US
dc.subject.hlbtoplevel Science en_US
dc.description.peerreviewed Peer Reviewed en_US
dc.contributor.affiliationum Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan en_US
dc.contributor.affiliationother Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; Department of Biostatistics/Epidemiology and Preventive Health Sciences, School of Health Sciences and Nursing, University of Tokyo, Tokyo, Japan ; Dana-Farber Cancer Institute, 44 Binney Street, SM 275 Boston, MA 02115 en_US
dc.contributor.affiliationother Division of Exploratory Research, Institution of Medical Science, The University of Tokyo, Tokyo, Japan en_US
dc.contributor.affiliationother Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan en_US
dc.contributor.affiliationother Department of Cell Therapy and Transplantation Medicine, University of Tokyo Hospital, Tokyo, Japan en_US
dc.contributor.affiliationother Department of HSCT Data Management, Nagoya University School of Medicine, Nagoya, Japan en_US
dc.contributor.affiliationother Department of Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Ishikawa, Japan en_US
dc.contributor.affiliationother Department of Hematology, Toranomon Hospital, Tokyo, Japan en_US
dc.contributor.affiliationother Medical Corporation Kouryokai CPC Clinic, Kagoshima, Japan en_US
dc.contributor.affiliationother Division of Hematology, Ehime Prefectural Central Hospital, Ehime, Japan en_US
dc.contributor.affiliationother Department of Hematology and Immunology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan en_US
dc.contributor.affiliationother Department of Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, Osaka, Japan en_US
dc.contributor.affiliationother Department of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan en_US
dc.contributor.affiliationother Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan en_US
dc.contributor.affiliationother Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan en_US
dc.contributor.affiliationother Department of Biostatistics/Epidemiology and Preventive Health Sciences, School of Health Sciences and Nursing, University of Tokyo, Tokyo, Japan en_US
dc.contributor.affiliationother Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan en_US
dc.identifier.pmid 17570513
dc.description.bitstreamurl http://deepblue.lib.umich.edu/bitstream/2027.42/56131/1/20977_ftp.pdf en_US
dc.identifier.doi http://dx.doi.org/10.1002/ajh.20977 en_US
dc.identifier.source American Journal of Hematology en_US
dc.owningcollname Interdisciplinary and Peer-Reviewed
 Show simple item record

This item appears in the following Collection(s)


Search Deep Blue

Advanced Search

Browse by

My Account

Information

Coming Soon


MLibrary logo